A phase II study to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC who developed isolated CNS progression (T790M negative or unknown) during 1st or 2nd generation EGFR-TKI or systemic disease progression (T790M negative) after treatment with 1st or 2nd generation EGFR-TKI and platinum-based chemotherapy (WJOG12819L)

Kazuhiko Nakagawa (Coordinating Investigator)0 个研究点目标入组 70 人开始时间: 2020年5月29日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1.Age of 20 years or older at the time of informed consent
•2.Histologically or cytologically confirmed nonsquamous NSCLC
•3.Locally advanced or recurrent cancer not amenable to curative surgical or radical radiation therapy
•4.Evidence of any EGFR-TKI-sensitive mutation (including G719X, exon 19 deletion, L858R, and L861Q) before the first EGFR-TKI therapy
•5.Never treated with a third-generation EGFR-TKI (e.g., osimertinib, ASP8273, CO-1686)
•6.ECOG performance status of 0 to 2 and life expectancy of>=12 weeks
•7.The Cohort 1- or Cohort 2-specific criteria must be met.
•Only Cohort 1
•- Disease progression of brain metastatic lesions alone without progression of extracranial lesions is radiologically diagnosed during first- or second-generation EGFR-TKI therapy.
•- Asymptomatic metastatic brain tumor with longest diameter of >=5mm, which has not been treated with radiation therapy.
•- A brain metastasis tissue (e.g., surgery) or plasma sample collected after progression of brain metastasis during first- or second-generation EGFR-TKI therapy meets sensitive mutation-positive (G719X, exon 19 deletion, L858R, or L861Q) and T790M-negative, neither sensitive mutation nor T790M is detectable (no analysis results are available), or testing is not feasible.
•Only Cohort 2
•- Progression is radiologically diagnosed after first- or second-generation EGFR-TKI therapy and platinum-based chemotherapy.
•- tumor collected after disease progression during first- or second-generation EGFR-TKI therapy shows that the disease is sensitive mutation-positive (G719X, exon 19 deletion, L858R, or L861Q) and T790M-negative.

排除标准

•1.CTCAE grade 1 or higher toxicity related to prior therapy persisting at the start of study treatment
•2.Spinal cord compression or symptomatic brain metastasis.
•3.Severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding tendency, or evidence of active infection, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) infection.
•4.Intractable nausea or vomiting, chronic gastrointestinal disease, inability to swallow medication, or history of major bowel resection that interferes with complete absorption of osimertinib
•5.QTc >470 msec, clinically important abnormality in cardiac rhythm, conduction, or waveform in resting ECG, factors that increase the risk of QTc prolongation or arrhythmic event:
•6.History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroid therapy, or evidence of clinically active interstitial lung disease
•7.Reduced bone marrow or organ function
•8.History of hypersensitivity to active or inactive ingredients of osimertinib or drugs that are chemically or pharmacologically similar to osimertinib
•9.Pregnant or lactating women
•10.Concurrent cancer
•11.Not qualified for the study, in the opinion of the investigator, when the patient is unlikely to comply with the study procedures, restrictions, or requirements

研究者

发起方

Kazuhiko Nakagawa (Coordinating Investigator)

相似试验

已完成

2 期

A phase II trial on efficacy and safety of osimertinib in elderly EGFR T790M-positive non-small-cell lung cancer patients who progressed during prior EGFR-TKI treatment or had recurrenceadvanced / recurrent non-small cell lung cancer (NSCLC)

JPRN-UMIN000022553Clinical Research Support Center Kyushu35

进行中（未招募）

1 期

Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinibEGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-003012-51-DKAstraZeneca AB360

招募中

1 期

Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinibEGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer

CTIS2024-512564-58-00AstraZeneca AB360

已完成

2 期

SAVANNAHCarcinoma

JPRN-jRCT2080224881AstraZeneca KK23

尚未招募

2 期

A trial to learn if taking Osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell lung cancer (NSCLC) that cannot be treated with surgery

CTRI/2024/06/069176Fortrea Development India Private Limited